TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16261778

Group type: EXPERIMENTAL
Intervention: Angio-Seal (AS)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Bio-DISC (BD)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Manual Compression (MC)
Number of subjects: 463
Study: 12406522

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10090869

Group type: EXPERIMENTAL
Intervention: Media-led community education campaign
Number of subjects: 933

Group type: COMPARATOR
Intervention: Control group (women in Los Angeles and Orange Counties)
Number of subjects: 933
Study: 7562387

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31161241

Group type: EXPERIMENTAL
Intervention: Anteromedial (AM) technique
Number of subjects: 106

Group type: COMPARATOR
Intervention: Transtibial (TT) technique
Number of subjects: 106
Study: 28295414

Group type: EXPERIMENTAL
Intervention: Treatment (not specified)
Number of subjects: 1383
Study: 26442394

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 0.5 mg.kg(‐1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 64
Study: 23561842

Group type: EXPERIMENTAL
Intervention: Environmental change intervention
Number of subjects: 179

Group type: COMPARATOR
Intervention: Delayed treatment control condition
Number of subjects: 179
Study: 17822764

Group type: EXPERIMENTAL
Intervention: Home visiting program (HFAK)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control group (no home visiting)
Number of subjects: 325
Study: 16201937

Group type: EXPERIMENTAL
Intervention: Meropenem (500 mg IV q8h)
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Imipenem-cilastatin (500 mg IV q8h)
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1076
Study: 12899226

Group type: EXPERIMENTAL
Intervention: 4 mg doxazosin daily for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10599899

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (3 hours/week for three months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual activities of daily living (Control group)
Number of subjects: 27
Study: 8566836

Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (ASA) 650 mg three times daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Effervescent calcium carbasalate (ECC) 826.8 mg three times daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (ASA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Effervescent calcium carbasalate (ECC)
Number of subjects: 20
Study: 2011771

Group type: EXPERIMENTAL
Intervention: d-penicillamine (500 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: d-penicillamine
Number of subjects: 26
Study: 7091871

Group type: EXPERIMENTAL
Intervention: 0.12 ppm ozone exposure (O2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Purified air (Control)
Number of subjects: 25
Study: 31828275

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study: 29981438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 27306620

Group type: EXPERIMENTAL
Intervention: 5 mg apixaban twice daily (n=9120)
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin (target INR range 2.0-3.0; n=9081)
Number of subjects: 18201

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study: 24992623

Group type: EXPERIMENTAL
Intervention: Normal Glucose Tolerance (NGT) at baseline
Number of subjects: 4566

Group type: EXPERIMENTAL
Intervention: Prediabetes at baseline
Number of subjects: 4566

Group type: EXPERIMENTAL
Intervention: Individuals maintaining NGT during follow-up
Number of subjects: 4566

Group type: EXPERIMENTAL
Intervention: Individuals progressing to T2D from NGT or prediabetes
Number of subjects: 4566

Group type: EXPERIMENTAL
Intervention: Individuals regressing from prediabetes to NGT
Number of subjects: 4566
Study: 22912453

Group type: EXPERIMENTAL
Intervention: 5% CM
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: 5% LM
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: 2.5% CM + 2.5% LM (blend)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Control
Number of subjects: 432
Study: 18678242

Group type: EXPERIMENTAL
Intervention: 8-week Mindfulness-based stress reduction (MBSR) program
Number of subjects: 48

Group type: COMPARATOR
Intervention: 1-day control seminar
Number of subjects: 48
Study: 18807583

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg tablet formulation A
Number of subjects: 20

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg tablet formulation B
Number of subjects: 20
Study: 16297323

Group type: EXPERIMENTAL
Intervention: Reduced Glutathione (GSH) 1.2 g/d through intravenous drip for 7 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no GSH)
Number of subjects: 45
Study: 12117045

Group type: EXPERIMENTAL
Intervention: FEV1/FEV6
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: FEV1/FVC
Number of subjects: 5887
Study: 10100041

Group type: EXPERIMENTAL
Intervention: SRP
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: SRP + metronidazole tabs 200 mg tds for 7 days
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: SRP + 2 subgingival applications of 25% metronidazole gel
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (non-smokers)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 84
Study: 7748020

Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 53

Group type: COMPARATOR
Intervention: Omnivorous diet (Control)
Number of subjects: 53
Study: 2336545

Group type: EXPERIMENTAL
Intervention: Sclerotherapy and propranolol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sclerotherapy only
Number of subjects: 29
Study: 85106

Group type: EXPERIMENTAL
Intervention: Bay g 6575 (1.2 g daily for 1 week)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bay g 6575 (1.2 g single dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bay g 6575 and dipyridamole (combined administration)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dipyridamole (alone)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Bay g 6575 (alone)
Number of subjects: 6
Study: 31400765

Group type: EXPERIMENTAL
Intervention: 6.5% isomaltulose-electrolyte beverage
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2% isomaltulose (CHO-2%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study: 29220860

Group type: EXPERIMENTAL
Intervention: Willingness to participate in a randomized trial deferring resection of diminutive polyps until the next surveillance colonoscopy
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Willingness to defer resection of diminutive polyps outside of a clinical trial
Number of subjects: 557

Group type: COMPARATOR
Intervention: Factors associated with willingness to defer resection
Number of subjects: 557
Study: 27583214

Group type: EXPERIMENTAL
Intervention: Aminobisphosphonate solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 24
Study: 25444700

Group type: EXPERIMENTAL
Intervention: Home perineal electrostimulation (HPES)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 161
Study: 21890864

Group type: EXPERIMENTAL
Intervention: Bed height at mid-thigh
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Bed height at anterior superior iliac spine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Bed height at xiphisternum
Number of subjects: 101
Study: 20059657

Group type: EXPERIMENTAL
Intervention: Primary repair without inflatable penile prosthesis (IPP)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Resistive index (RI) cutoff of <0.80
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Penile duplex ultrasonography (PDU)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dynamic infusion cavernosometry and cavernosography (DICC)
Number of subjects: 26
Study: 17722961

Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 0
Study: 15743729

Group type: COMPARATOR
Intervention: African-American children
Number of subjects: 222
Study: 11753000

Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg neostigmine administered upon reappearance of the first tactile TOF response (group I)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg neostigmine administered upon reappearance of the second tactile TOF response (group II)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg neostigmine administered upon reappearance of the third tactile TOF response (group III)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg neostigmine administered upon reappearance of the fourth tactile TOF response (group IV)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no neostigmine administration)
Number of subjects: 64
Study: 10508797

Group type: EXPERIMENTAL
Intervention: MC(+) (n = 58) with a control unit measuring effective compliance
Number of subjects: 121

Group type: COMPARATOR
Intervention: MC(−) (n = 63) without a control unit measuring effective compliance
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both groups (MC(+) and MC(−))
Number of subjects: 121

Group type: COMPARATOR
Intervention: Previous study
Number of subjects: 121
Study: 8834628

Group type: EXPERIMENTAL
Intervention: Occupational exposure to manganese
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2283012

Group type: EXPERIMENTAL
Intervention: PGE2‐gel (Prepidil) intravaginal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 30
Study: 7053334

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (nonsteroidal estrogen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogens, orchiectomy, or both
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen treatment
Number of subjects: 0
Study: 30236471

Group type: EXPERIMENTAL
Intervention: Additional supervised physical activity (median of 20 additional minutes per day for a median of 16.5 days)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Social activities (control group)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Additional supervised physical activity
Number of subjects: 198
Study: 26957836

Group type: EXPERIMENTAL
Intervention: Anti-vascular endothelial growth factor agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New pharmacologic agents
Number of subjects: 0
Study: 24328907

Group type: COMPARATOR
Intervention: Betamethasone valerate 0.1% cream (BMVc)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment (TACo)
Number of subjects: 20
Study: 22521875

Group type: EXPERIMENTAL
Intervention: 100mg hydrocortisone given as a rapid intravenous bolus
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 20679600

Group type: EXPERIMENTAL
Intervention: SNR (Sentinel lymph node resection)
Number of subjects: 749

Group type: COMPARATOR
Intervention: SNAD (SNR followed by axillary dissection)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Both SNAD and SNR
Number of subjects: 749
Study: 18187209

Group type: EXPERIMENTAL
Intervention: Orofacial myofunctional evaluation with scores (OMES)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional orofacial myofunctional evaluation (TOME)
Number of subjects: 80
Study: 16328453

Group type: EXPERIMENTAL
Intervention: 0 degrees C cold pain stimulus
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: intradermal injection of 50 microg capsaicin without cooling
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: injection of capsaicin followed by application of 0 degrees C cold pain stimulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: 30 degrees C neutral stimulus
Number of subjects: 14
Study: 14971086

Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 0
Study: 10853874

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 2617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2617
Study: 8792266

Group type: EXPERIMENTAL
Intervention: Auditory training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Listening to unmodified music
Number of subjects: 80
Study: 1473164

Group type: EXPERIMENTAL
Intervention: Allylestrenol (30 mg/d initially, reduced to 5 mg/d after 15 days)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lynestrenol (10 mg/d initially, reduced to 1.25 mg/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 6143138

Group type: EXPERIMENTAL
Intervention: Maintenance of activity, anti-inflammatory and antirheumatic drugs, and systemic steroids where necessary
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest and anti-inflammatory and antirheumatic drugs
Number of subjects: 0
Study: 30559259

Group type: EXPERIMENTAL
Intervention: Sutimlimab (10 mg/kg test dose followed by 60 mg/kg full dose 1 to 4 days later and 3 additional weekly doses of 60 mg/kg)
Number of subjects: 10
Study: 30324924

Group type: EXPERIMENTAL
Intervention: SAP P11-4
Number of subjects: 24

Group type: COMPARATOR
Intervention: CPP-ACP (control)
Number of subjects: 24
Study: 27797093

Group type: EXPERIMENTAL
Intervention: Selective Spinal Lidocaine (SS-L): 3 mL of 0.8% lidocaine solution (24 mg lidocaine, 15 μg fentanyl)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional Dose Lidocaine (CD-L): 5 mL of 1% lidocaine solution (50 mg lidocaine, 25 μg fentanyl)
Number of subjects: 84
Study: 25361563

Group type: EXPERIMENTAL
Intervention: PCPPP treatment group
Number of subjects: 0
Study: 22243622

Group type: EXPERIMENTAL
Intervention: Hand hygiene with soap and water
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub
Number of subjects: 683

Group type: COMPARATOR
Intervention: Control
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Soap and water
Number of subjects: 683
Study: 19823863

Group type: EXPERIMENTAL
Intervention: Membrane blue
Number of subjects: 30

Group type: COMPARATOR
Intervention: Infracyanine green
Number of subjects: 30
Study: 18060250

Group type: EXPERIMENTAL
Intervention: Factor IX aptamers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Von Willebrand factor aptamers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic pharmacobiologic therapy
Number of subjects: 0
Study: 16128945

Group type: EXPERIMENTAL
Intervention: Bi-weekly endoscopic variceal ligation (EVL)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Bi-monthly endoscopic variceal ligation (EVL)
Number of subjects: 63
Study: 12401580

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus followed by a 4 mg/min infusion during operation and 4 mg/kg in the priming solution of CPB)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 10460126

Group type: EXPERIMENTAL
Intervention: Pedaling at 60 rpm
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Kicking dominant leg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Non-dominant leg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Overall subject sample
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Individual subjects
Number of subjects: 11
Study: 7798579

Group type: EXPERIMENTAL
Intervention: Low-fat controlled diet plus 20 g corn bran supplement
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-fat controlled diet plus 20 g wheat bran supplement
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-fat controlled diet
Number of subjects: 29
Study: 2086820

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CXM-AX) 250 mg t.i.d. for 3-7 days
Number of subjects: 251

Group type: COMPARATOR
Intervention: Cefaclor (CCL) 250 mg t.i.d. for 3-7 days
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CXM-AX)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Cefaclor (CCL)
Number of subjects: 251
Study: 765515

Group type: EXPERIMENTAL
Intervention: 600,000 units of penicillin G benzathine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 1.2 million units of penicillin G benzathine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 600,000 units of penicillin G benzathine and 600,000 units of penicillin G procaine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 900,000 units of penicillin G benzathine and 300,000 units of penicillin G procaine
Number of subjects: 400
Study: 31027892

Group type: EXPERIMENTAL
Intervention: Everolimus with Tacrolimus (EVR/TAC)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Everolimus with Cyclosporine (EVR/CsA)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Mycophenolic Acid with Tacrolimus (MPA/TAC)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 338
Study: 28679681

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 19
Study: 26115983

Group type: EXPERIMENTAL
Intervention: Novel four quadrant technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Haptic feedback
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patellar cutting guide
Number of subjects: 90
Study: 24118640

Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg plus metformin 1000 mg bid
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg plus metformin 500 mg bid
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg bid
Number of subjects: 566

Group type: COMPARATOR
Intervention: Metformin 500 mg bid
Number of subjects: 566

Group type: COMPARATOR
Intervention: Linagliptin 5 mg qd
Number of subjects: 566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study: 16451766

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse (CHX)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Herbal rinse (HBR)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 15102334

Group type: EXPERIMENTAL
Intervention: Observed Length of Stay (LOS) for patients with inefficient care
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Observed Length of Stay (LOS) for patients with acceptable efficiency
Number of subjects: 374

Group type: COMPARATOR
Intervention: Function for predicting LOS
Number of subjects: 374

Group type: COMPARATOR
Intervention: Age as a predictor of LOS
Number of subjects: 374

Group type: COMPARATOR
Intervention: Response to treatment as a predictor of LOS
Number of subjects: 374

Group type: COMPARATOR
Intervention: Dummy for personality disorders as a predictor of LOS
Number of subjects: 374

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT) as a predictor of LOS
Number of subjects: 374

Group type: COMPARATOR
Intervention: Factor for sexual and/or eating symptoms as a predictor of LOS
Number of subjects: 374

Group type: COMPARATOR
Intervention: Factor for psychotic symptoms as a predictor of LOS
Number of subjects: 374

Group type: COMPARATOR
Intervention: ROC curve for detecting inefficiencies
Number of subjects: 374
Study: 10939601

Group type: COMPARATOR
Intervention: 5-FU plus FA (arm A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 5-FU plus FA plus IFO (arm B)
Number of subjects: 48
Study: 8729156

Group type: EXPERIMENTAL
Intervention: BMI and waist-to-hip ratio (WHR)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Age and other factors combined
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Ethnicity (African-American and Hispanic women)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Alcohol intake, cigarette smoking, physical activity, parity, education, and income
Number of subjects: 869

Group type: COMPARATOR
Intervention: Age
Number of subjects: 869
Study: 1422487

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (Allo‐BMT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (Auto‐BMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy (Chemo)
Number of subjects: 40
Study: 2998786

Group type: EXPERIMENTAL
Intervention: 100 mg Metoprolol (beta 1‐selective)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 80 mg Propranolol (non‐selective)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 30449521

Group type: EXPERIMENTAL
Intervention: Web-based learning module (Radiopaedia.org)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Traditional learning material
Number of subjects: 47
Study: 28820949

Group type: EXPERIMENTAL
Intervention: Synthetic cartilage implant MTPJ1 hemiarthroplasty
Number of subjects: 176

Group type: COMPARATOR
Intervention: First metatarsophalangeal joint arthrodesis
Number of subjects: 176
Study: 25867139

Group type: EXPERIMENTAL
Intervention: elpamotide + gemcitabine
Number of subjects: 153

Group type: COMPARATOR
Intervention: placebo + gemcitabine
Number of subjects: 153
Study: 24499493

Group type: EXPERIMENTAL
Intervention: NRL001 5 mg, 7.5 mg, or 10 mg in 1 or 2 g suppositories
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NRL001 10 mg, 12.5 mg, or 15 mg in 1 or 2 g suppositories
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NRL001 doses (1 g and 2 g)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NRL001 doses
Number of subjects: 48
Study: 20927112

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 1021
Study: 19345644

Group type: EXPERIMENTAL
Intervention: EVT 201 1.5 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: EVT 201 2.5 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 17351300

Group type: EXPERIMENTAL
Intervention: Sprinkles 12.5 mg ferrous fumarate
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Sprinkles 20 mg ferrous fumarate
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Sprinkles 30 mg ferrous fumarate
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Sprinkles 20 mg micronized ferric pyrophosphate
Number of subjects: 432

Group type: COMPARATOR
Intervention: DROPS 20 mg ferrous glycine sulphate
Number of subjects: 432